510(k) Report

510(k) · Cleared

Cleared

Rapid Drug Screen 5-Panel Drug Screening Test for Cocaine, Marijuana, Opiates, Amphetamine and Methamphetamine

K993796510(k) TraditionalCleared Dec 21, 199942-day reviewClass II21 CFR 862.3870

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

American Bio Medica Corp. · LDJ Enzyme Immunoassay, Cannabinoids

Cleared on Dec 21, 1999 as substantially equivalent to K984525 (American Bio Medica Corp., 1999) after a 42-day review. Its family tree reaches back 2 generations to 1997.

Decided
Dec 21, 1999
Review
42 days
Class
Class II
Product code
LDJ
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K964900 (1997). No later device cites it as a predicate yet.

  1. Root · 2 generations backK964900 Rapid Drug ScreenAmerican Bio Medica Corp. · 1997
  2. 1 generation backK984525 Rapid Drug Screen 5-Panel with Methamphetamine TestAmerican Bio Medica Corp. · 1999
  3. This deviceK993796 Rapid Drug Screen 5-Panel Drug Screening Test for Cocaine…American Bio Medica Corp. · 1999
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K964900Rapid Drug ScreenAmerican Bio Medica Corp.1997—
−1K984525Rapid Drug Screen 5-Panel with Methamphetamine TestAmerican Bio Medica Corp.1999—
0 (this device)K993796Rapid Drug Screen 5-Panel Drug Screening Test for Cocaine, Marijuana, Opiates…American Bio Medica Corp.1999—
FIG. 1 — Lineage of K993796, 1997–1999Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LDJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LDJ device

  1. #1 K232732 Rapid Marijuana (THC) Test Strip 20, Rapid…score 9.4 · 10 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K984525Rapid Drug Screen 5-Panel with Methamphetamine Test
Summary page 1
…nce with the requirements of 21 CFR 807.92. The assigned 510(k) is: Predicate Devices: American Bio Medica “Rapid Drug Screen” 5-Panel test kit with Methamphetamine (K-984525) All of the assays employed in the Rapid Drug Screen panels are based on the same principle of highly specific reaction between…
American Bio Medica Corp.1999—

Also cleared against K984525: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 2 years and passes through 1 company; a new generation was cleared every 1.9 years on median.
  • None of the 2 ancestors has a recall.
  • 1 other device also cites its predicate K984525.

How does its category compare?

All LDJ devices

LDJ Enzyme Immunoassay, Cannabinoids: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LDJ

2in 2024

2008: 22009: 12011: 42012: 42013: 32014: 22015: 32016: 12019: 12023: 12024: 2
2007high 4 (2011) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LDJ

48in 2015

2011: 219 days median2012: 193 days median2013: 162 days median2015: 48 days median
2007high 219 (2011) · low 48 (2015)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LDJ

1in 2023

2008: 42023: 1
2007high 4 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LDJ

1in 2015

2015: 1
2007high 1 (2015) · low 0 (2007)2025

MAUDE reports naming product code LDJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20082—40
20091—00
20100—00
2011421900
2012419300
2013316200
20142—00
201534801
20161—00
20170—00
20180—00
20191—00
20200—00
20210—00
20220—00
20231—10
20242—00
20250—00
20260—0—

What is it indicated for?

“Rapid Drug Screen” 5-panel with cocaine, marijuana, opiates, amphetamine and methamphetamine is a lateral flow immunoassay for the simulatenous detection in urine of five abused drugs at stated detectable limits. (Each assay occupies a seperate channel). It is intended for use in the qualitative detection of d-Amphetamine (1000 ng/ml), Benzoyl ecgonine (300 ng/ml), Cannabinoids (50 ng/ml), Methamphetamines (1000 ng/ml) and Opiates (300 ng/ml). “Rapid…

Read the full statement (191 words)

“Rapid Drug Screen” 5-panel with cocaine, marijuana, opiates, amphetamine and methamphetamine is a lateral flow immunoassay for the simulatenous detection in urine of five abused drugs at stated detectable limits. (Each assay occupies a seperate channel). It is intended for use in the qualitative detection of d-Amphetamine (1000 ng/ml), Benzoyl ecgonine (300 ng/ml), Cannabinoids (50 ng/ml), Methamphetamines (1000 ng/ml) and Opiates (300 ng/ml).

“Rapid Drug Screen” is intended for professional use. It is not intended for over the counter sale to non-professionals. The assays are easy to perform, but should not be used without proper supervision. These immuno-assays are simplified qualatative screening methods that provides only a preliminary result for use in the need for aditional or confirmatory testing, i.e., gas-chromatography/mass spectrometry (GC/MS).

“Rapid Drug Screen” provides only a preliminary analytical test result. A more specific alternate chemical method must be used to obtain a more confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical and professional judgement should be applied to any drug of abuse test result, particulary when preliminary positive results are used.

“Rapid Drug Screen” is not intended as a point of care test.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K993796: Rapid Drug Screen 5-Panel Drug Screening Test for Cocaine, Marijuana, Opiates, Amphetamine and Methamphetamine.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K993796

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026